Interestingly, in a phase II trial of nivolumab for high-risk stage IB–IIIA NSCLC patients in neoadjuvant setting, comparing to pre-treatment, an influx of PD-1+CD8+ T cell infiltration in TME after treatment was associated with clinical response.44 Here, CD8A is linked to non-small cell lung carcinoma.